Trial Profile
Randomized Study Demonstrating That Octreotide Fluid Crystal Provides Sustained Octreotide Bioavailability and Similar IGF-1 Suppression to Octreotide LAR (Sandostatin LAR) in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Feb 2015
Price :
$35
*
At a glance
- Drugs Octreotide (Primary) ; Octreotide
- Indications Acromegaly; Carcinoid tumour; Diarrhoea; Intestinal obstruction; Neuroendocrine tumours; Polycystic liver disease; Prostate cancer; Thymoma
- Focus Pharmacodynamics; Pharmacokinetics
- 23 Feb 2015 New trial record